Baxter (NYSE: BAX) reported Q3 EPS of $0.83, $0.10 better than the analyst estimate of $0.73. Revenue for the quarter came in at $2.97 billion versus the consensus estimate of $2.83 billion.

GUIDANCE:

Baxter sees FY2020 EPS of $3.02-$3.05, versus the consensus of $3.06.

• For full-year 2020, Baxter expects sales growth compared to the prior-year period to be up low single digits on a reported, constant currency and operational basis. The company expects U.S. GAAP earnings of $2.41 to $2.44 per share and adjusted earnings, before special items, of $3.02 to $3.05 per share. This outlook assumes, among other things, low double digit declines in hospital admissions and mid-single digit declines in surgical volumes in the fourth quarter 2020 as compared to pre-COVID levels.

For earnings history and earnings-related data on Baxter (BAX) click here.